Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pioglitazone versus glibenclamide or metformin in diet-treated adults with type 2 diabetes
ACTRN12608000534381Phase 3Completed
- Sponsor
- Takeda
- Start
- Sep 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of pioglitazone in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Takeda. Primary endpoint: Change from baseline in C-reactive protein. Started Sep 2004; status: completed.
02
Drugs
pioglitazone
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ACTRN12608000534381.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12608000534381.